Ensoma
Soumitra Roy brings to Ensoma more than 25 years of experience in vector development for gene therapy, both in academia and in industry. Prior to Ensoma, he worked on adenoviral and adeno-associated virus (AAV) vector development at the gene therapy program at the University of Pennsylvania and at Johnson & Johnson (Janssen Vaccines), greatly expanding the repertoire of available adenoviral vector serotypes, as well as designing capsid mutants.
This person is not in any offices
Ensoma
1 followers
Ensoma believes every person, no matter where they are, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of their Engenious™ vectors, their therapies can be delivered in a simple, single injection.